 |
|
Retinal Vein Occlusion (BRVO/CRVO)
Retinal Vein Occlusion occurs when blood flow through a retinal vein becomes blocked causing macular edema, retinal hemorrhages, and decreased vision. Vein occlusions occur in the young as well as elderly population. Until very recently, treatment has been very limited for these conditions.
Current clinical trials for RVO:
Genentech BRAVO
A Phase III , multicenter, randomized, sham injection controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to Branch retinal vein occlusion.
Genentech CRUISE
A Phase III multicenter, randomized sham injection controlled study of the efficacy and safety of Ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion.
Patients enter either Genentech BRAVO or Genentech CRUISE, and then upon completion of either, become a candidate for Genentech HORIZON.
Genentech HORIZEN
An open label extension study to evaluate the safety and tolerability of Ranibizumab in subjects with RVO who have completed a Genentech sponsored Ranibizumab study.
To explore this section, please choose from the menu on the left.
